-
Uncategorized1 week agoHouse bill aims to crack down on China biotech deals
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking...
-
Uncategorized1 week ago
Immune Response Activated by RNA Splicing Opens Targeted Therapies
In a new study published in Nature Communications titled, “Native long-read RNA sequencing of human monocytes reveals activation-induced alternative splicing toward functional isoforms,” researchers at University Medical Center...
-
Uncategorized1 week ago
ASCO’s biggest winners showcased a new era of cancer innovation
Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations,...
-
Uncategorized1 week ago
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their...
-
Uncategorized1 week agoSTAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in...
-
Uncategorized1 week ago
NewLimit snags $435M after seeing age reversal in human liver cells
NewLimit snags $435M after seeing age reversal in human liver cells
-
Uncategorized1 week agoSTAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days...
-
Uncategorized1 week agoIs the military fueling eating disorders?
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. As discussed, it’s Ice Cream Every...
-
Uncategorized1 week ago
Celcuity slides even after ‘practice-changing’ late-stage breast cancer data
Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.
-
Uncategorized1 week ago
Travere beefs up rare kidney disease portfolio with up to $1.1B China deal
Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
